Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer

Hawa Nalwoga1,4*, Lavina Ahmed1,2, Jarle B. Arnes3, Henry Wabinga4, Lars A. Akslen1,3*

1 Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway, 2 BerGenBio AS, Bergen, Norway, 3 Department of Pathology, Haukeland University Hospital, Bergen, Norway, 4 Department of Pathology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda

¤ Current address: Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Norway
* lars.akslen@uib.no

Abstract

Purpose
Inhibition of hypoxia-inducible factor (HIF) and Axl receptor tyrosine kinase is being evaluated for targeted therapy in solid tumors. Both HIF-1α and Axl influence tumor growth and metastatic potential, and they have been linked to treatment failure in many cancers. However, there is a lack of reports on HIF-1α expression in African breast cancer, which has a poor prognosis, and novel treatment targets must therefore be established. Here, we aimed to evaluate HIF-1α in relation to Axl expression, angiogenesis markers, and other tumor characteristics in a series of African breast cancer.

Methods
Using immunohistochemistry, we examined 261 invasive breast cancers on tissue microarrays for HIF-1α and Axl as well as several other markers, and a subset of 185 cases had information on VEGF (vascular endothelial growth factor) expression, microvessel density (MVD), proliferating microvessel density (pMVD) and vascular proliferation index (VPI) for important comparisons.

Results
Strong HIF-1α expression was associated with increased Axl (p = 0.007), VEGF (p<0.0005), and p53 (p = 0.032) expression, as well as high tumor cell proliferation by Ki-67 (p = 0.006), and high tumor grade (p = 0.003). Tumors with strong HIF-1α expression had significantly higher MVD (p = 0.019) and higher pMVD (p = 0.027) than tumors with weak expression.
Conclusions
High HIF-1α expression is significantly associated with Axl and VEGF expression, and with markers of poor prognosis in this series of breast cancer, suggesting HIF-1α and Axl as potential therapeutic targets in African breast cancer.

Introduction
Breast cancer is the most common malignancy affecting females worldwide, and it caused about 500,000 deaths in 2012, which is about 15% of all cancer deaths in women [1]. Metastases represent a major reason for cancer-related deaths; about 30% of breast cancer patients initially diagnosed with early-stage disease will eventually develop distant metastases [2]. Studies have shown that breast cancer is a heterogeneous disease, and understanding the molecular events that underlie this heterogeneity will lead to more precise and effective therapy. Regarding breast cancer in Africans and African Americans, previous studies have revealed that it has more aggressive features, is usually diagnosed in later stages, and has a poorer prognosis than breast cancer among Caucasians [3–5]. The reasons for this have not been fully characterized [4].

Tumor microenvironment factors have major influences on tumor development, growth and metastasis. As one factor, tumor hypoxia has been linked to aggressive phenotypes with associated chemoresistance and treatment failures in various cancer types, including breast cancer [6–9]. Hypoxia is also known as a key stimulus for angiogenesis, mainly via hypoxia-inducible factor 1 (HIF-1) [6, 9], which regulates transcription of several genes mediating tumor responses to hypoxia such as tumor cell proliferation, survival, migration and angiogenesis [6, 8]. During tumor hypoxia, HIF-1 is a main regulator of vascular endothelial growth factor (VEGF) and modulates angiogenesis by up-regulating the VEGF gene [6, 9, 10]. Vascular endothelial growth factor, one of the main factors responsible for the angiogenic switch during tumorigenesis, is a crucial mediator of angiogenesis in breast cancer [6, 8, 11]. Sustained angiogenesis is one of the hallmarks of cancer [12] and is a complex multi-step process, being essential for tumor growth, invasion and metastatic spread [6, 11, 13].

HIF-1α is a subunit of the HIF-1 heterodimer protein that is protected from degradation during the hypoxic response [6, 8, 14] when there is up-regulation of its mRNA with stabilization of the protein product and nuclear localization [6]. Previous evidence shows that HIF-1α is involved in breast tumorigenesis [15] and modifies tumor growth rates and their metastatic potential [6, 8, 16]. Moreover, HIF-1α is over-expressed in about 24–56% of invasive breast cancers [17–21] or even more and has been associated with increased VEGF expression [15, 20], increased angiogenesis [21], higher tumor grade [15, 20], as well as treatment failure and poor prognosis [7, 19]. In experimental breast cancer models, resistance or sensitivity to EGFR-targeted therapies was dependent on HIF-1α activity in triple negative cell lines [22].

Several previous studies have revealed that hypoxia can independently stimulate the epithelial–mesenchymal transition (EMT) program, a critical step in cancer progression and metastasis, probably via a number of mechanisms [6, 8] such as HIF-1α signaling in several human tumors and cell lines: breast, pancreas, colon, kidney, lung and others [16, 23]. Furthermore, in-vitro and in-vivo studies have confirmed that hypoxia-induced EMT is tightly regulated by HIF-signaling pathways, which also contribute to additional tumor invasiveness by late release of VEGF, being mediated and sustained by HIF-1α [6, 8, 23]. Regulation of transcription factors Twist and ZEB1 has been shown to play a critical role in the hypoxia-mediated EMT process to promote metastasis [8, 16, 24].
Stimulation of EMT via transcription regulators such as Twist or ZEB1 has been associated with up-regulation of Axl, a tyrosine kinase receptor, in breast cancer epithelial cells [25], while a study of prostate cancer revealed that Axl expression was sustained in hypoxic tumor microenvironments [26]. Actually, Axl has been reported to have similar functions as HIF-1α in tumorigenesis such as promoting cell survival, migration, angiogenesis, invasion and metastasis among others [8, 25, 27]. According to previous studies, Axl might be a crucial regulator of EMT and is involved in the metastatic process in breast, prostate and lung cancers [26, 27], acting in both tumor cells and the supporting stroma [27, 28]. Previously, we reported a strong expression of Axl in breast cancer among African women [29].

Here, we aimed to explore HIF-1α expression in a series of African breast cancers in relation to Axl expression and other tumor characteristics. We found that strong HIF-1α expression was associated with increased Axl expression, markers of angiogenesis and other characteristics of aggressive tumors in this cohort of African breast cancer. Our results suggest that the therapeutic implications of HIF-1α and Axl co-expression in breast cancer should further be explored.

**Materials and Methods**

**Patient series and specimens**

This study was approved by the Research and Ethics Committee (REC) at Makerere University College of Health Sciences (MakCHS), Kampala, Uganda and the Regional Committee for Medical and Health Research Ethics (REC) of Western Norway (approval ID# 2014/1984/REK Vest). The REC at MakCHS waived the need for informed consent in accordance with the Uganda National Council for Science and Technology guidelines for conducting such a study. Initially, a total of 277 cases of primary invasive breast carcinoma with available archival paraffin blocks from the period 1990–2011 were identified as previously described from the records and archives at Department of Pathology, School of Biomedical Sciences at MakCHS, Kampala, Uganda [30]. Clinical information on the cases was obtained from histology reports, whereas information on treatment and follow-up was not available. Patient age ranged from 18 to 80 years (mean = 46 years, standard deviation 12.9). Tumor size was available in 60 patients and ranged from 1 to 20 cm (mean = 5.4 cm, standard deviation 3.2; median 5.0 cm). A majority of the tumors (50/60, 83%) were more than 2.0 cm in size. All cases were re-examined histologically and typed according to WHO recommendations [31], and histologic grading was performed in accordance with the Nottingham criteria [32]. Nuclear grade and mitotic count were recorded as separate variables using the same criteria [30].

**Immunohistochemistry**

Tissue microarray (TMA) blocks were constructed, and 5 μm thick sections were made by standard technique and used for immunostaining as previously described [30]. We also included, for comparison, results for a subgroup of this series that had been previously stained (Table 1) for other biomarkers like estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, p53, aldehyde dehydrogenase 1 (ALDH1), c-KIT, Cytokeratin 5/6, P-cadherin and epidermal growth factor receptor (EGFR) [33, 34] in addition to previous information regarding tumor-associated angiogenesis [35].

Regarding VEGF, HIF-1α and Axl staining, sections were deparaffinized in xylene, rehydrated through a series of graded alcohols and rinsed in distilled water. Antigen retrieval was achieved by microwave oven (MD 122, Whirlpool Nordic OY, Bromma, Sweden) heating in retrieval buffer (VEGF, Tris-EDTA pH 9.0; HIF-1α, citrate buffer pH 6.0) at 750 Watts for 10 minutes followed by 350 Watts for 15 minutes (an extra 20 minutes at 350 Watts was added for
HIF-1α. For Axl, heating in target retrieval buffer pH6 (DakoCytomation [Dako], Glostrup, Denmark, S1699) in a 6th Sense Jetchef Microwave Oven (JT 366, Whirlpool Nordic OY, Bromma, Sweden) for 25 minutes was utilized. All sections were allowed to cool at room temperature for 20 minutes, and then thoroughly rinsed in wash buffer solution. Additional staining was performed either by auto staining (VEGF and HIF-1α) in a Dako autostainer or manually (Axl antibody). Endogenous peroxidase activity was blocked by incubating sections with 0.03% hydrogen peroxidase (Dako, S2001) containing sodium azide for 5 minutes (VEGF and HIF-1α) or 15 minutes (Axl), followed by rinsing with wash buffer solution. In addition, to further reduce non-specific staining due to Axl antibody, we used the following: a background reducing antibody diluent (Dako, S3022) for dilution, a protein blocking serum (Dako, X0909) for 5–15 min before each step of antibody incubation, and rinsed the slides with several changes of wash buffer solution containing Tween 20 (Dako, S3306) in between the steps. Sections were incubated with specific antibodies either at room temperature (VEGF, dilution 1:20) or overnight at 4°C (HIF-1α, dilution 1:20; Axl, dilution 1:800). For Axl staining, a secondary rabbit anti-goat antibody from SouthernBiotech, Birmingham, AL (Catalog # 6164-01, dilution 1:400) was applied for 30 minutes at room temperature after three changes of wash buffer. Antigens were detected by incubating sections using appropriate Dako EnVision+ system-HRP kits (VEGF and Axl) or Dako Flex-EnVision kit (HIF-1α) for 30–35 minutes. After rinsing the sections in wash buffer solution, we developed the peroxidase by incubating with freshly prepared 3,3′-diaminobenzidine chromogen solution for 10 minutes (VEGF and HIF-1α) and

Table 1. Details of immunohistochemistry with antibodies and staining procedures.

| Biomarker | Antibody | Clone | Dilution | Incubation time (min) |
|-----------|----------|-------|----------|-----------------------|
| HIF-1α    | MCM AH Anti-HIF-1 alpha antibody, (Santa Cruz Biotechnology Cat# sc-53546, RRID:AB_629639) | H1α 67 | 1:20 | Overnight |
| Axl       | Goat Anti-Human Axl Affinity Purified Polyclonal antibody (R and D Systems Cat# AF154, RRID:AB_354852) | Polyclonal | 1:800 | Overnight |
| Cytokeratin 5/6 | MCM AH Cytokeratin 5/6 antibody (Dako Cat# M7237, RRID:AB_2281083) | D5/16 B4 | 1:200 | 30 |
| EGFR      | MCM AH Anti-EGFr Antibody, (Life Technologies Cat# 280005, RRID:AB_10835059) | 31G7 | 1:30 | 30 |
| P-cadherin| MCM AH P-Cadherin antibody (BD Biosciences Cat# 610227, RRID:AB_2077667) | 56 | 1:400 | 60 |
| ER        | MCM AH Estrogen receptor α (Dako Cat# M7047, RRID:AB_2101946) | 1D5 | 1:50 | 30 |
| PR        | MCM AH Progesterone receptor antibody (Dako Cat# M3569, RRID:AB_2532076) | PgR 636 | 1:150 | 30 |
| HER2      | PCR AH c-erbB-2, c-neu antibody (Dako Cat# A0485, RRID:AB_2335701) | Polyclonal | 1:500 | 60 |
| Ki-67     | MCM AH Ki-67 antibody (Dako Cat# M7240, RRID:AB_2142367) | MIB-1 | 1:50 | 60 |
| p53       | MCM AH p53 Tumor Suppressor Protein antibody (Dako Cat# M7001, RRID:AB_2206626) | DO-7 | 1:1000 | 60 |
| VEGF      | MCM AH VEGF antibody, (R and D Systems Cat# MAB293, RRID:AB_358222) | 26503 | 1:20 | 60 |

Previously stained markers [30, 35]

| Biomarker | Antibody | Clone | Dilution | Incubation time (min) |
|-----------|----------|-------|----------|-----------------------|
| ALDH1     | MCM AH Purified anti-Aldehyde dehydrogenase antibody (BD Biosciences Cat# 611195, RRID:AB_398729) | 44 | 1:250 | 60 |
| VPI       | PCR AH Von Willebrand factor (Dako Cat# A0082, RRID:AB_2315602)& MCM AH Ki-67 antibody (Dako Cat# M7240, RRID:AB_2142367) | Polyclonal & MIB-1 | 1:800 & 1:50 | 60 |
| c-KIT     | PCR AH CD 117 (c-Kit, SCF-Receptor) antibody (Dako Cat# A4502, RRID:AB_2335702) | Polyclonal | 1:200 | 30 |

VPI, vascular proliferation index.

aMCM AH, monoclonal mouse anti-human.
bPCR AH, polyclonal rabbit anti-human.

doi:10.1371/journal.pone.0146823.t001

HIF-1α. For Axl, heating in target retrieval buffer pH6 (DakoCytomation [Dako], Glostrup, Denmark, S1699) in a 6th Sense Jetchef Microwave Oven (JT 366, Whirlpool Nordic OY, Bromma, Sweden) for 25 minutes was utilized. All sections were allowed to cool at room temperature for 20 minutes, and then thoroughly rinsed in wash buffer solution. Additional staining was performed either by auto staining (VEGF and HIF-1α) in a Dako autostainer or manually (Axl antibody). Endogenous peroxidase activity was blocked by incubating sections with 0.03% hydrogen peroxidase (Dako, S2001) containing sodium azide for 5 minutes (VEGF and HIF-1α) or 15 minutes (Axl), followed by rinsing with wash buffer solution. In addition, to further reduce non-specific staining due to Axl antibody, we used the following: a background reducing antibody diluent (Dako, S3022) for dilution, a protein blocking serum (Dako, X0909) for 5–15 min before each step of antibody incubation, and rinsed the slides with several changes of wash buffer solution containing Tween 20 (Dako, S3306) in between the steps. Sections were incubated with specific antibodies either at room temperature (VEGF, dilution 1:20) or overnight at 4°C (HIF-1α, dilution 1:20; Axl, dilution 1:800). For Axl staining, a secondary rabbit anti-goat antibody from SouthernBiotech, Birmingham, AL (Catalog # 6164–01, dilution 1:400) was applied for 30 minutes at room temperature after three changes of wash buffer. Antigens were detected by incubating sections using appropriate Dako EnVision+ system-HRP kits (VEGF and Axl) or Dako Flex-EnVision kit (HIF-1α) for 30–35 minutes. After rinsing the sections in wash buffer solution, we developed the peroxidase by incubating with freshly prepared 3,3′-diaminobenzidine chromogen solution for 10 minutes (VEGF and HIF-1α) and
3 minutes (Axl). Sections were then rinsed in distilled water and counter stained with hematoxylin.

**Immunohistochemical assessment**

A total of 16 tumors (5.8%) without interpretable cores containing sufficient tumor tissue were omitted from the analysis, and the remaining cases were evaluated for markers like HIF-1α, Axl, ER, PR, HER2, Ki-67 and p53 (Table 1). A subgroup of 192 tumors had information from previous studies [30, 33, 34] on VEGF expression, angiogenesis markers (see below), ALDH1 and c-KIT for important comparisons; 185 cases were fit for VEGF evaluation. For all markers, evaluation was done by visual microscopic assessment. Positive immunoreactivity was considered as follows (see also S1 Table): for HIF-1α and VEGF, nuclear and cytoplasmic staining were evaluated as being positive, respectively, while membrane and cytoplasmic staining was recorded for Axl; for HIF-1α cytoplasmic staining was observed in some cases but was not recorded; nuclear staining was assessed for ER, PR, Ki-67, p53 and c-KIT; cell membrane staining was considered for HER2 and EGFR; cell membrane and cytoplasmic expression was recorded for c-KIT, as previously indicated [30, 33–35]; cytoplasmic staining was evaluated for ALDH1, while nuclear staining alone was considered nonspecific and was not recorded [30].

Staining was assessed by a semi-quantitative and subjective grading system that considers intensity of staining and proportion of tumor cells showing positive staining. For most of the markers, a staining index (values = 0–9) was determined by multiplying the score for intensity of staining (none = 0, weak = 1, moderate = 2 and strong = 3) with the score for proportion of tumor cells stained (< 10% = 1, 10%–50% = 2, >50% = 3).

Cut-points for positive expression of the various markers are shown in S1 Table, as previously reported [33–35]. Briefly, the cut-off values for the SI categories used in statistical analysis were based on median or quartile values, also considering the frequency distribution and size of the subgroups. Based on the median staining index, the cut-off values were set at 0–2 = negative or weak expression and 3–9 = strong (high) expression for HIF-1α, VEGF, Axl and ALDH1 [30]. Similarly, a cut-point based on median SI for this series, SI = 0–3 as negative and SI = 4–9 as positive, was used for P-cadherin, whereas the upper quartile (SI = 0–4 as negative and SI = 6–9 as positive) was applied for p53 staining. Staining index for CK5/6 showed a high proportion of negative cases, and tumors were therefore categorized by SI = 0 as negative and SI = 1–9 as positive. For EGFR staining, tumors with any cell membrane staining, whether circumferentially complete or incomplete, observed in more than 1% of the tumor cells, were considered as positive [36]. Tumors were considered positive for ER, PR and c-KIT when at least 10% of the tumor cells were stained (weakly, moderately or strongly). Regarding HER2 status, cases were considered positive when the HER2 IHC score was 3+, whereas cases with 0–2+ scores were categorized as negative in this study. After determining the proportion (%) of Ki-67 positively stained nuclei out of 500 tumor cells counted at high power magnification (x400) using an eyepiece grid, the cut-point for high tumor cell proliferation rate by Ki-67 was set at 20.0% based on the median value as previously described [30].

Information on angiogenesis markers was available for a subset of the cases (n = 192) from previous studies and were included in the present study for important comparisons [35]. Briefly, tumor-associated angiogenesis was assessed by using dual staining with Factor VIII and Ki-67 antibodies, on regular tissue sections, as reported [35]. All positively stained vessels (red), within the hot-spots, most often in the tumor periphery, were counted including vessels without microlumina and clusters of endothelial cells clearly separate from adjacent microvessels in accordance to Weidner’s approach [37]. Dividing endothelial cells recognized...
by co-expression of Factor VIII and Ki-67: red cells (Factor VIII) with blue nuclei (Ki-67) were counted as proliferating microvessels [35]. Concisely, microvessel density (MVD) was taken as the number of vessels counted and expressed as MVD per mm\(^2\), while proliferating microvessel density (pMVD) was the number of microvessels with proliferating endothelial cells expressed per mm\(^2\). The percentage of pMVD (mm\(^2\)) to the total MVD (mm\(^2\)) was defined as vascular proliferation index (VPI). Altogether, 177 cases were fit for univariate statistical analysis using non-parametric tests; 15 cases (7.8%) were excluded due to poorly stained or insufficient tumor tissue [35].

**Molecular subtyping**

Based on our previous studies [30], we defined various basal-like phenotypes (BLPs) as concurrent ER\(^-\), HER2\(^-\) and: CK5\(^+\) as BLP1; P-cadherin\(^+\) as BLP2; EGFR\(^+\) as BLP3; CK5\(^+\) and/or EGFR\(^+\) as BLP4; and BLP5 as concurrent ER\(^-\), HER2\(^-\) and positivity of at least one basal markers (CK5, P-cadherin and EGFR). BLP4 corresponds to the core basal phenotype described previously by Nielsen et al [38]. In addition, we determined molecular subtypes using immunohistochemistry in accordance with a slightly modified Goldhirsch et al criteria [39], where <20% = low and \(\geq 20\%\) = high were used ascut-points for Ki-67 score [29]. Thus, tumors were classified as follows: luminal A subtype (ER\(^+\) and/or PR\(^+\), HER2\(^-\) and Ki-67 \(\geq 20\%\)), luminal B subtype (luminal B, HER2 negative [ER\(^+\) and/or PR\(^+\), HER2\(^-\) and Ki-67 \(\geq 20\%\)]) and luminal B HER2 positive [ER\(^+\) and/or PR\(^+\) and HER2\(^+\)], HER2 subtype (ER\(^-\), PR\(^-\) and HER2\(^+\)), basal-like subtype (ER\(^-\), PRL\(^-\), HER2\(^-\) and CK 5/6\(^+\) and/or EGFR\(^+\)) and unclassified category (ER\(^-\), PR\(^-\), HER2\(^-\), CK 5/6\(^-\) and EGFR\(^-\)).

**Statistical analysis**

Statistical analysis was performed using the IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp, Armonk, NY). Associations between different categorical variables were assessed using the Pearson’s \(\chi^2\) test, while for quantitative data, the median values were compared using Mann-Whitney U test, and a \(p\)-value of \(< 0.05\) was considered significant for any statistical test used.

**Results**

A majority (229/261; 88%) of the tumors were invasive carcinoma of no special type (NST) and of these, 134 (59%) were grade 3. In total, 165 of 261 tumors (63%) showed strong HIF-1\(\alpha\) expression (Fig 1), and this was significantly associated with higher histologic grade (\(p = 0.037\)) and nuclear grade (\(p = 0.008\)). Furthermore, 188 of 243 tumors (77\%) strongly expressed Axl, and this finding was associated with higher histologic grade as well (\(p < 0.0005\)) (Fig 2B). Additionally, strong HIF-1\(\alpha\) expression was significantly associated with strong Axl expression, high VEGF expression, high Ki-67 proliferative rate in tumor cells, and stronger p53 expression (Table 2).

There was no significant association between HIF-1\(\alpha\) or VEGF expression and basal markers, basal-like phenotypes, triple negative phenotype (ER\(^-\), PR\(^-\), HER2\(^-\)) (Table 3), ALDH1 and c-KIT expression (Table 4). Strong Axl expression was associated with the basal-like subtype (odds ratio 3.0, 95\% confidence interval 1.2–7.5, \(p = 0.016\)) compared to the luminal A subtype, whereas it showed only a weak association with P-cadherin (\(p = 0.045\)) and no association with the other basal markers (S2 Table).

In addition, Table 4 shows the median values for weak and strong expression categories of HIF-1\(\alpha\) and VEGF. Tumors with strong HIF-1\(\alpha\) expression had significantly higher MVD (\(p = 0.019\)) and pMVD (\(p = 0.027\)) than tumors with weak HIF-1\(\alpha\) expression. Similarly,
tumors with strong VEGF expression had significantly higher MVD (p = 0.007), pMVD (p = 0.004) and VPI (p = 0.019) than tumors with weak VEGF expression.
Discussion

Previous studies have reported that HIF-1 is involved in breast tumorigenesis [15] by influencing growth rate and metastatic potential [8, 9] and consequently leading to an association with poor prognosis [17, 19, 40]. Our present findings indicate that this is also the case in African breast cancer since we found strong associations of HIF-1α expression with features of aggressive tumors. In particular, the association of HIF-1α with high histologic and nuclear grade extends previous literature indicating that the level of HIF-1α expression increases with the degree of malignancy [9, 15, 18].

The process of epithelial–mesenchymal transition (EMT), an important tumor progression program, can be activated by hypoxia, probably via a number of mechanisms such as HIF-1α signaling, in several human tumors and cell lines [6, 16, 23, 24]. At the same time, hypoxia is a well-known angiogenesis activator by production of HIF-1 transcriptional factors [6]. Hypoxia-inducible factors induce EMT by up-regulation of transcription regulators such as Twist, Snail, Slug and Zeb in several cell types [6, 24] during the EMT process. Also, the receptor
tyrosine kinase Axl is known to be activated by epithelial–mesenchymal transition [25]. Interestingly, a study of prostate cancer has revealed that Axl expression was sustained in hypoxic tumor microenvironments [26]. Here, we report a strong co-expression of HIF-1α and Axl in this breast cancer cohort, supporting previous findings that Axl expression is increased within hypoxic tumor areas [26]. Notably, hypoxia has been found to prevent GAS6-mediated down-regulation of Axl in prostate cancer cells [26].

We here found that HIF-1α was strongly associated with VEGF expression in this series of African breast cancer, as also reported in other populations [15, 20, 40], although some did not

| Table 2. HIF-1α and associations with clinico-pathologic tumor and molecular characteristics. |
| --- |
| Variable | HIF-1α Weak (SI = 0–2) (n; %) n = 96 | HIF-1α Strong (SI = 3–9) (n; %) n = 165 | OR 95% CI | P-value |
| Age in years | | | | |
| <50 | 57 (41) | 81 (59) | | 1 |
| ≥50 | 33 (33) | 67 (67) | 1.4 (0.8–2.4) | NS |
| Histologic type | | | | |
| Ductal carcinoma (NST) | 80 (35) | 149 (65) | | 1 |
| Others | 16 (50) | 16 (50) | 0.5 (0.3–1.1) | NS |
| Histologic grade | | | | |
| Grade 1 | 16 (57) | 12 (43) | | 1 |
| Grade 2 | 32 (39) | 51 (61) | 2.1 (0.9–5.1) | 0.086 |
| Grade 3 | 48 (32) | 102 (68) | 2.8 (1.2–6.5) | 0.011 |
| Nuclear grade | | | | |
| Grade 1 | 24 (57) | 18 (43) | | 1 |
| Grade 2 | 38 (35) | 72 (65) | 2.5 (1.2–5.2) | 0.011 |
| Grade 3 | 34 (31) | 75 (69) | 3.0 (1.4–6.1) | 0.003 |
| Mitotic count | | | | |
| 0–6 | 22 (46) | 26 (54) | | 1 |
| 7–13 | 8 (18) | 37 (82) | 3.9 (1.5–10.1) | 0.004 |
| >13 | 66 (39) | 102 (61) | 1.3 (0.7–2.5) | NS |
| Ki-67 proliferative rate | | | | |
| Low (<20.0%) | 52 (45) | 63 (55) | | 1 |
| High (≥20.0%) | 41 (29) | 101 (71) | 2.0 (1.2–3.4) | 0.007 |
| p53 expression | | | | |
| Low, SI = 0–4 | 74 (41) | 105 (59) | | 1 |
| High, SI = 6–9 | 21 (27) | 58 (73) | 1.9 (1.1–3.5) | 0.023 |
| ER expression | | | | |
| Positive (≥10%) | 33 (34) | 65 (66) | | 1 |
| Negative (<10%) | 61 (38) | 99 (62) | 0.8 (0.5–1.4) | NS |
| PR expression | | | | |
| Positive (≥10%) | 19 (28) | 49 (72) | | 1 |
| Negative (<10%) | 73 (39) | 115 (61) | 0.6 (0.3–1.1) | NS |
| HER2 expression | | | | |
| Negative, score 0–2+ | 74 (36) | 133 (64) | | 1 |
| Positive, score 3+ | 20 (40) | 30 (60) | 0.8 (0.4–1.6) | NS |
| Axl expression | | | | |
| Weak, SI = 0–2 | 29 (53) | 26 (47) | | 1 |
| Strong, SI = 3–9 | 62 (33) | 126 (67) | 2.3 (1.2–4.2) | 0.008 |

SI, staining index; NST, no special type; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
doi:10.1371/journal.pone.0146823.t002
find an association between HIF-1α and VEGF [18, 21]. Therefore, our results provide more support that HIF-1 is involved in angiogenesis by influencing VEGF transcription [10]. As a novel finding, HIF-1α expression was significantly associated with microvessel proliferation, a marker of activated angiogenesis [41]. In addition, strong VEGF expression was significantly associated with higher vascular proliferation, as well as overall vascular density, and our results

Table 3. HIF-1α and VEGF associations with basal markers, basal-like phenotypes and subtypes.

| Variable | HIF-1α Weak (SI = 0–2) (n; %) n = 96 | HIF-1α Strong (SI = 3–9) (n; %) n = 165 | P-value | VEGF Weak (SI = 0–2) (n; %) n = 55 | VEGF Strong (SI = 3–9) (n; %) n = 130 | P-value |
|----------|-------------------------------------|----------------------------------------|---------|------------------------------------|--------------------------------------|---------|
| CK 5/6 expression | | | | | | |
| Negative, SI = 0 | 79 (36) | 138 (64) | 45 (29) | 110 (71) | | |
| Positive, SI = 1–9 | 15 (38) | 25 (62) | 8 (29) | 20 (71) | | |
| P-cad expression | | | | | | |
| Negative, SI = 0–3 | 71 (38) | 116 (62) | 41 (31) | 93 (69) | | |
| Positive, SI = 4–9 | 25 (35) | 47 (65) | 13 (26) | 37 (74) | | |
| EGFR expression | | | | | | |
| Negative (≤1%) | 70 (34) | 134 (66) | 44 (30) | 102 (70) | | |
| Positive (>1%) | 24 (44) | 30 (56) | 10 (28) | 26 (72) | | |
| BLP1 | | | | | | |
| Absent | 80 (36) | 141 (64) | 45 (29) | 111 (71) | | |
| Present | 13 (37) | 22 (63) | 8 (30) | 19 (70) | | |
| BLP2 | | | | | | |
| Absent | 77 (38) | 128 (62) | 45 (32) | 98 (68) | | |
| Present | 18 (33) | 37 (67) | 9 (22) | 32 (78) | | |
| BLP3 | | | | | | |
| Absent | 76 (35) | 140 (65) | 47 (31) | 105 (69) | | |
| Present | 18 (42) | 25 (58) | 7 (23) | 24 (77) | | |
| BLP4 (CBP) | | | | | | |
| Absent | 71 (35) | 132 (65) | 42 (30) | 100 (70) | | |
| Present | 22 (40) | 33 (60) | 12 (29) | 29 (71) | | |
| BLP5 | | | | | | |
| Absent | 68 (36) | 121 (64) | 42 (31) | 92 (69) | | |
| Present | 25 (37) | 43 (63) | 12 (25) | 37 (75) | | |
| TNP | | | | | | |
| No | 55 (36) | 100 (65) | 33 (31) | 74 (69) | | |
| Yes | 38 (37) | 65 (63) | 21 (27) | 56 (73) | | |
| Subtype | | | | | | |
| Luminal A | 21 (38) | 35 (62) | 18 (38) | 29 (62) | | |
| Luminal B | 16 (27) | 43 (73) | 7 (19) | 30 (81) | | 0.054 |
| HER2 | 16 (44) | 20 (56) | 8 (36) | 14 (64) | | NS |
| Basal-like (CBP) | 22 (40) | 33 (60) | 12 (29) | 29 (71) | | NS |
| Unclassified | 16 (33) | 32 (67) | 9 (25) | 27 (75) | | NS |

CK, cytokeratin; P-cad, P-cadherin; TNP, triple negative phenotype; CBP, Core basal phenotype

doi:10.1371/journal.pone.0146823.t003
support the importance of the VEGF pathway for angiogenesis in African breast cancer. Taken together, the findings indicate that anti-angiogenesis treatment could be an option in this population of aggressive and often late-stage breast cancer [3, 5]. Also, simultaneous targeting of VEGF and HIF-1 pathways would be a possibility supported by our data. Indeed, results from recent Phase I clinical trials with combined down-regulation of HIF-1α activity and a monoclonal antibody to VEGF are promising [42, 43]. Combinations with anti-Axl treatment [44] is another possibility indicated by our findings.

Additionally, a strong association between HIF-1α expression and Ki-67 proliferative rate in tumor cells was seen in our study. Our results, as well as previous studies [15, 18, 20, 40], support that HIF-1 factors promote major processes like tumor cell proliferation [6, 9] and support a hypothesis that Ki-67 proliferative rate might have a predictive role in classification of patients with VEGF positive high grade tumors for possible benefit from HIF-1α targeted therapy [45].

We found no significant associations between HIF-1α and ALDH1 or c-KIT expression. In experimental studies, HIF-1α was up-regulated in CSC-like cells that showed elevated ALDH1 expression [46], and ALDH1 was found to be associated with HIF-1α in locally advanced breast cancer [47]. Whereas studies in breast cancer cells have indicated that HIF-1α crucially regulates expression of stem cell factor (SCF), a c-KIT ligand [48], results on small-cell lung

### Table 4. HIF-1α and VEGF association with Axl, ALDH1, and c-KIT markers of tumor angiogenesis.

| Variable | HIF-1α Weak (SI = 0–2) n = 54 | HIF-1α Strong (SI = 3–9) n = 128 | P-value | VEGF Weak (SI = 0–2) n = 55 | VEGF Strong (SI = 3–9) n = 130 | P-value |
|----------|-------------------------------|-------------------------------|---------|-------------------------------|-------------------------------|---------|
| **Axl expression** | | | | | | |
| Weak, SI = 0–2 | 20 (49) | 21 (51) | 0.002 | 20 (49) | 21 (51) | 0.001 |
| Strong, SI = 3–9 | 30 (24) | 96 (76) | | 27 (21) | 100 (79) | |
| **VEGF expression** | | | | | | |
| Weak, SI = 0–2 | 29 (55) | 24 (45) | | <0.0005 | | |
| Strong, SI = 3–9 | 24 (19) | 103 (81) | | | | |
| **ALDH1 expression** | | | | | | |
| Negative, SI = 0–2 | 31 (33) | 62 (67) | | 32 (34) | 63 (66) | |
| Positive, SI = 3–9 | 21 (24) | 65 (76) | | 21 (24) | 67 (76) | |
| **c-KIT expression** | | | | | | |
| Negative (<10%) | 52 (30) | 121 (70) | | 53 (30) | 122 (70) | |
| Positive (≥10%) | 1 (13) | 7 (87) | | 0 (0) | 8 (100) | |
| **MVD/mm²** | | | | | | |
| Median | 42.9 | 56.9 | 0.019 | 44.0 | 57.0 | 0.007 |
| **pMVD/mm²** | | | | | | |
| Median | 0.4 | 0.9 | 0.027 | 0.2 | 0.9 | 0.004 |
| **VPI (%)** | | | | | | |
| Median | 0.9 | 1.6 | NS | 0.6 | 1.5 | 0.019 |

SI, staining index; VEGF, vascular endothelial growth factor; MVD, microvessel density; pMVD, proliferating microvessel density; VPI, vascular proliferation index.

*shows association within the smaller cohort

bP value was calculated using Pearson’s χ² test.
cP value was calculated using Mann-Whitney U test.

doi:10.1371/journal.pone.0146823.t004
cancer cells indicated that activated SCF-c-KIT stimulated HIF-1α-mediated VEGF expression via PI3K/Akt activation [49].

Angiogenesis is related to both p53 and HER2 signaling pathways. Wild-type p53 suppresses VEGF transcription [50] and at the same time inhibits HIF-1α activity through targeting it for degradation. The decreased ubiquitylation of HIF-1α that follows loss of p53 function results in increased HIF-1α activity [51], which consequently promotes angiogenesis. It has been suggested that knowledge of both p53 mutation status and HIF-1α expression may influence choice of chemotherapy and HIF-1 inhibitors in cancer treatment [52]. In support of previous studies [20, 53], we found a significant association between p53 expression and strong HIF-1α staining. Further, experimental studies indicate that HER2 signaling is implicated in up-regulation of VEGF via mediators such as HIF-1α transcription factor to promote tumor angiogenesis [54, 55], and HIF-1α expression correlated with the HER2 subtype and HER2 positivity in breast cancers [18, 40, 56]. However, such associations were not found in our present study, in line with others [7, 19].

An inverse relationship between HIF-1α expression and ER status has been indicated in both human tumors and in experimental models [18, 57], although this relationship is still discussed. Our results showed no association between HIF-1α and ER expression in agreement with previous studies [17, 19]. More studies are required to determine the precise relationship between HIF-1α angiogenic drive and negative ER status.

Further, HIF-1α/VEGF is an important signaling pathway in breast cancer angiogenesis [58], while VEGF has been suggested as a candidate biomarker for the basal-like breast cancer [59], but we found no association between HIF-1α/VEGF and various basal markers in this cohort, in contrast to some other studies on basal-like tumors [60–62], triple negative breast cancers [63] and breast cancer cell lines [64]. HIF-1α expression was reported to correlate with P-cadherin expression in human breast carcinomas [61], while Gatza et al. [64] used six breast cancer cell lines to show that basal-like and triple negative cells expressed higher levels of HIF-1α mRNA compared to luminal cell lines. For VEGF expression, some results indicate that VEGF expression correlated with CK 5/6, and the basal-like subtype was more likely than luminal A tumors to express VEGF [60]. A similar finding was reported by Ribeiro-Silva et al. [62] in a smaller study although they used only a single marker CK5 positivity to define the basal-like subtype. On the contrary, lack of association between HIF-1α/VEGF and the basal-like phenotype or triple negative subtype in our study agrees well with previous findings in human carcinomas [65–67]. Thus, apart from methodological differences, our findings could suggest that additional angiogenic HIF-1 independent factors [68] are important for the angiogenic drive in African breast cancer. Martin et al. [4], using genome-wide mRNA expression profiles, noted that pathways related to angiogenesis might function differently between patients with African ancestry and Caucasians. Generally, we agree with Lindner et al. [69] that race is an important factor to consider when planning optimal therapeutic strategies for patients.

In conclusion, there is a frequent expression of HIF-1α in this series of breast cancer from an African population, which is significantly associated with strong Axl co-expression in addition to associations with other factors of poor prognosis like VEGF expression and increased angiogenesis, high tumor cell proliferation by Ki-67 rate, p53 expression, as well as high histologic tumor grade. Thus, HIF-1α and Axl as potential therapeutic targets in African breast cancer might be considered.

Supporting Information
S1 Table. Immunoreactivity evaluation criteria for the biomarkers in the present study. (DOCX)
Acknowledgments

We acknowledge the Department of Pathology at MakCHS for allowing us to use the archival tissue, the Kampala Cancer Registry for providing us with the data and Centre for Disease Control and Prevention (CDC) for computerizing the data base at the Pathology Department (MakCHS). In addition, we appreciate the excellent technical support offered by Sarah Nambooze, Ruth Nakigudde, Dorothy Lynn Nabbale, Gerd Lillian Hallseth and Bendik Nordanger. We likewise extend our thanks to all the staff of the Gades Laboratory for Pathology and Centre for Cancer Biomarkers (CCBIO) for their support during the study. This work was partly supported by the Research Council of Norway through its Centers of Excellence funding scheme, project number 223250. The study was also supported by the Norwegian Cancer Society, Helse Vest RHF, and the Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen.

Author Contributions

Conceived and designed the experiments: HN HW LAA. Performed the experiments: HN LA JBA. Analyzed the data: HN. Contributed reagents/materials/analysis tools: HN LA HW LAA. Wrote the paper: HN LAA. Conceived and designed the collaborative study: HW LAA HN. Performed histopathological re-assessment or immunohistochemical staining and assessment of cases: HN LA JBA. Drafted the manuscript: HN. Critically revised the manuscript: LAA. Read and approved the final manuscript: HN LA JBA HW LAA.

References

1. Schnitt SJ, Lakhani SR. Breast cancer. In: Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: IACR; 2014. pp. 362–364.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013; 274(2):113–126. Epub 2013/07/13. doi:10.1111/joim.12084 PMID: 23844915
3. Amadori D, Serra P, Bravaccini S, Farolfi A, Puccetti M, Carretta E, et al. Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations. Breast Cancer Res Treat. 2014; 145(1):177–183. doi: 10.1007/s10549-014-2903-0 PMID: 24658893
4. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, et al. Differences in the tumor micro-environment between African-American and European-American breast cancer patients. PLoS One. 2009; 4(2):e4531. Epub 2009/02/20. doi: 10.1371/journal.pone.0004531 PMID: 19225562
5. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110(4):876–884. doi: 10.1002/cncr.22836 PMID: 17620276
6. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta. 2012; 1826(2):272–296. doi: 10.1016/j.bbacli.2012.04.006 PMID: 22579961
7. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006; 12(15):4562–4568. doi: 10.1158/1078-0432.CCR-05-2690 PMID: 16899602
8. Liu Z-J, Semenza GL, Zhang H-f. Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B. 2015; 16(1):32–43. doi: 10.1631/jzus.B1400221 PMID: PMC4289442
9. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59 (22):5930–5935. PMID: 10582706
10. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604–4613. PMID: 8756616

11. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353–364. doi: 10.1016/S0092-8674(00)81018-7 PMID: 8756718

12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57–70. Epub 2000/01/27. doi: 10.1016/S0092-8674(00)81683-9 PMID: 10647931

13. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusioglu B, et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997; 3(11):1222–1227. doi: 10.1038/nm1197-1222 PMID: 9359696

14. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38–47. Epub 2002/03/21. doi: 10.1038/nrc704 PMID: 11902584

15. Bos R, Zhong H, Hanahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst. 2001; 93(4):309–314. doi: 10.1093/jnci/93.4.309 PMID: 11181778

16. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008; 10(3):295–305. doi: 10.1038/ncb1691 PMID: 18297062

17. Gruber G, Greiner RH, Hlushchuk R, Aebbersold DM, Altermatt HJ, Berclaz G, et al. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 2004; 6(3):R191–198. doi: 10.1186/bcr775 PMID: 15084243

18. Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G. Hypoxia-inducible factor-1alpha is a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38–47. doi: 10.1038/ncb1691 PMID: 18297062

19. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology. 2005; 46(1):31–36. doi: 10.1111/j.1365-2559.2005.02045.x PMID: 15656883

20. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008; 110(3):465–475. Epub 2007/09/07. doi: 10.1007/s10549-007-9742-1 PMID: 17805961

21. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology. 2005; 46(1):31–36. doi: 10.1111/j.1365-2559.2005.02045.x PMID: 15656883

22. El Guerrab A, Zegrou R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, et al. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One. 2011; 6(9):e25080. doi: 10.1371/journal.pone.0025080 PMID: 21966417

23. Cannito S, Novo E, Compagnone A, Valfrè di Bonzo L, Busletta C, Zamara E, et al. Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer. Carcinogenesis. 2008; 29(12):2267–2278. doi: 10.1093/carcin/bgn216 PMID: 18791199

24. Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie R, et al. HIF-1alpha Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer. PLoS One. 2015; 10(6):e0129603. doi: 10.1371/journal.pone.0129603 PMID: 26507751

25. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. Axl in an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. PNAS. 2010; 107(3):1124–1129. Epub 2010/01/19. doi: 10.1073/pnas.0909333107 PMID: 20080645

26. Mishra A, Wang J, Shiozawa Y, McGee S, Kim J, Jung Y, et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol Cancer Res. 2012; 10(6):703–712. doi: 10.1158/1541-7786.MCR-11-0569 PMID: 22516347

27. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009; 28(39):3442–3455. Epub 2009/07/28. doi: 10.1038/onc.2009.212 PMID: 19633687

28. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010; 70(4):1544–1554. Epub 2010/02/11. doi: 10.1158/0008-5472.CAN-09-2997 PMID: 20145120
29. Ahmed L, Nalwoga H, Arnes JB, Wabinga H, Micklem DR, Akslen LA. Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women. APMIS. 2015; 123 (8):688–696. doi: 10.1111/amp.12403 PMID: 26011102
30. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer. 2010; 102(2):369–375. Epub 2009/12/17. doi: 10.1038/sj.bjc.6605488 PMID: 20010944
31. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. WHO Classification of tumours: Pathology and genetics of tumours of the breast and female genital organs. Vol 5. Lyon, France: IARC Press; 2003. pp. 13–59.
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade. Br J Cancer. 1991; 64(1):463–469. doi: 10.1038/bjc.1991.253 PMID: 1757079
33. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Frequency of the basal-like phenotype in African breast cancer. APMIS. 2007; 115(12):1391–1399. doi: 10.1111/j.1600-0463.2007.00882.x PMID: 18184410
34. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of EGFR and c-kit is associated with the basal-like phenotype of breast cancer. Histopathology. 2011; 52(6):771–779. doi: 10.1111/j.1365-2553.2013.04515.x PMID: 23778413
35. Nalwoga H, Arnes JB, Stefansson IM, Wabinga H, Foulkes WD, Akslen LA. Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat. 2011; 130(3):1063–1071. Epub 2011/08/30. doi: 10.1007/s10549-011-1740-7 PMID: 21874512
36. Arnes JB, Collett K, Akslen LA. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology. 2008; 52(3):370–380. Epub 2008/02/14. doi: 10.1111/j.1365-2559.2007.02957.x PMID: 18269588
37. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1–8. PMID: 1701519
38. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16):5367–5374. doi: 10.1158/1078-0432.CCR-04-2220 PMID: 15328174
39. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736–1747. doi: 10.1093/annonc/mdr304 PMID: 21709140
40. Bos R, van der Groep P, Greijer AE, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003; 97(6):1573–1581. doi: 10.1002/cncr.11426 PMID: 12627523
41. Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 2006; 66(6):3303–3309. doi: 10.1158/0008-5472.CAN-05-1163 PMID: 16540684
42. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, et al. Targeting hypoxia-inducible factor-1alpha (HIF-1alpha) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014; 5(21):10280–10292. doi: 10.18632/oncotarget.2163 PMID: 25373733
43. Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, et al. Weekly EZN-2208 (PEGylated SN38) in combination with bevacizumab in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014; 73(2):343–348. doi: 10.1007/s00280-013-2362-z PMID: 24288262
44. Sheridan C. First Axl inhibitor enters clinical trials. Nat Biotechnol. 2013; 31(9):775–776. Epub 2013/09/12. doi: 10.1038/nbt0913-775a PMID: 24022140
45. Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melli G, et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014; 73(2):343–348. doi: 10.1007/s00280-013-2362-z PMID: 24292632
46. Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012; 103(6):1058–1064. doi: 10.1111/j.1349-7006.2012.02281.x PMID: 22457373
47. Tiezzi DG, Clagnan WS, Mandarano LR, de Sousa CB, Marana HR, Tiezzi MG, et al. Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer. Clinics (Sao Paulo). 2013; 68(5):592–596. doi: 10.6061/clinics/2013(05)03 PMID: 23778413
48. Han ZB, Ren H, Zhao H, Chi Y, Chen K, Zhou B, et al. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis. 2008; 29(10):1853–1861. doi: 10.1093/carcin/bgn066 PMID: 18339685
49. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther. 2006; 5(6):1415–1422. doi: 10.1158/1535-7163.MCT-05-0503 PMID: 16818499
50. Mukhopadhyay D, Tsiosk A, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995; 55(24):6161–6165. PMID: 8521408
51. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000; 14(13):34–44. doi: 10.1101/gad.14.1.34 PMID: 10640274
52. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, Schmitt CA, et al. Hypoxia-inducible factor 1 alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010; 5(8):e12038. doi: 10.1371/journal.pone.0012038 PMID: 20706634
53. Bos R, van Diest PJ, van der Groep P, Shvarts A, Greijer AE, van der Wall E. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res. 2004; 6(4):R450–459. Epub 2004/06/26. doi: 10.1186/bcr813 PMID: 15217513
54. Alameddine RS, Otrock ZK, Awada A, Shamseddine A. CROSSTALK BETWEEN HER2 SIGNALING AND ANGIOGENESIS IN breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol. 2013; 25(3):313–324. doi: 10.1097/CCO.0b013e3283e37f72 PMID: 23518599
55. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001; 21(12):3995–4004. Epub 2001/05/22. doi: 10.1128/MCB.21.12.3995-4004.2001 PMID: 11359907
56. Choi J, Jung WH, Koo JS. Metabolism-related proteins are differentially expressed according to the morphologic subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology. 2013; 80(1):41–52. doi: 10.1159/000339513 PMID: 22832328
57. Ryu K, Park C, Lee Y. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. Biochem Biophys Res Commun. 2011; 407(4):831–836. doi: 10.1016/j.bbrc.2011.03.119 PMID: 21458421
58. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech. 2002; 59(1):41–48. doi: 10.1002/jemt.10175 PMID: 12242695
59. Choo JR, Nielsen TO. Biomarkers for Basal-like Breast Cancer. Cancers. 2010; 2(2):1040–1065. doi: 10.3390/cancers2021040 PMID: 24261106
60. Liu Y, Tamimi RM, Collins LC, Gilmore HL, Schnitt SJ, Connolly JL, et al. The association between vascular endothelial growth factor expression and survival varies with intrinsic breast subtype. Breast Cancer Res. 2011; 13(3):R62. doi: 10.1186/bcr2899 PMID: 21627261
61. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009; 20(10):1639–1646. doi: 10.1093/annonc/mdp062 PMID: 19549711
62. Galzta ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res. 2011; 13(3):R62. doi: 10.1186/bcr2899 PMID: 21672245
63. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer. 2009; 100(2):405–411. doi: 10.1038/sj.bjc.6604844 PMID: 19165203
67. Yehia L, Boulos F, Jabbour M, Mahlouz Z, Fakhruddin N, El-Sabban M. Expression of HIF-1alpha and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. PLoS One. 2015; 10(6): e0129356. doi: 10.1371/journal.pone.0129356 PMID: 26046764

68. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007; 13(19):5670–5674. doi: 10.1158/1078-0432.CCR-07-0111 PMID: 17908955

69. Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, et al. Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PLoS One. 2013; 8(11):e71915. Epub 2013/11/22. doi: 10.1371/journal.pone.0071915 PMID: 24260093